The American Assoc. for the Study of Liver Disease (AASLD), which writes the
treatment guidelines for hepatitis B, has just updated treatment guidelines
for HBV. This is the first time they've done this in several years. The new
guidelines are at: http://cirrus.mail-list.com/hepatitis-b/67108567.html
The experts took up the following questions and issues when they wrote these
new guidelines (see below). I haven't read them yet but everyone should
review them to see if anything applies to their condition, and if they should
raise the new treatment recommendations with their doctors. Good luck, Chris
K
1. Should adults with immune active CHB be
treated with antiviral therapy to decrease liver-related
complications?
2. Should adults with immune-tolerant infection be
treated with antiviral therapy to decrease liver-related
complications?
3. Should antiviral therapy be discontinued in hepatitis
B e antigen (HBeAg)-positive persons who have
developed HBeAg seroconversion on therapy?
4. Should antiviral therapy be discontinued in persons
with HBeAg-negative infection with sustained
HBV DNA suppression on therapy?
5. In HBV-monoinfected persons, does entecavir therapy,
when compared to tenofovir therapy, have a
different impact on renal and bone health?
6. Is there a benefit to adding a second antiviral
agent in persons with persistent low levels of viremia
while being treated with either tenofovir or
entecavir?
7. Should persons with compensated cirrhosis and low
levels of viremia be treated with antiviral agents?
8. Should pregnant women who are hepatitis B surface
antigen (HBsAg) positive with high viral
load receive antiviral treatment in the third trimester
to prevent perinatal transmission of HBV?
9. Should children with HBeAg-positive CHB be
treated with antiviral therapy to decrease liverrelated
complications?作者: StephenW 时间: 2015-11-17 12:40